Anshuma Bansal1, Bhavana Rai1, Shikhar Kumar1, Vanita Suri1,2, Sushmita Ghoshal1. 1. Department of Radiotherapy, Nehru Hospital, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, India. 2. Department of Gynecology and Obstetrics, Nehru Hospital, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, India.
Abstract
BACKGROUND: The advent of effective chemotherapeutic agents for ovarian carcinoma has made radical abdomino-pelvic radiation redundant. Nevertheless, palliative pelvic radiotherapy still has a role in palliating local symptoms. However, its effect on progression-free survival (PFS) may be debated. AIMS: To study the outcome of fractionated palliative pelvic radiotherapy in relapsed ovarian cancers in terms of symptom control and PFS. METHODS: Twenty-three patients of ovarian cancers, heavily pretreated with chemotherapy and with recurrent or residual pelvic masses, were planned for palliative pelvic radiotherapy to the dose of 46-50 Gy in 23-25 fractions in 4.5-5 weeks. Symptom control and outcomes have been analyzed. RESULTS: Post-radiotherapy, abdominal pain was controlled in 15 out of 17 patients (88.2 %), bleeding per vaginum in all 5 patients and vaginal discharge stopped in 4 out of 5 patients (80 %). On follow-up, of 23 patients, 17 (74 %) had progressive disease post-radiation, and median time to disease progression was 10 months (range 1-49). On univariate analysis, increased PFS was observed in patients who received radiation late in their course of disease, those with serous histology, and with lesser disease bulk in pelvis (≤2 cm) prior to radiation initiation. CONCLUSION: Fractionated palliative pelvic radiotherapy is an efficient method for symptom palliation in relapsed ovarian cancers. Patients who are heavily pretreated with chemotherapy and have a small-volume pelvic disease may show a prolonged PFS with addition of pelvic radiotherapy. Indications of radiotherapy, however, need to be defined.
BACKGROUND: The advent of effective chemotherapeutic agents for ovarian carcinoma has made radical abdomino-pelvic radiation redundant. Nevertheless, palliative pelvic radiotherapy still has a role in palliating local symptoms. However, its effect on progression-free survival (PFS) may be debated. AIMS: To study the outcome of fractionated palliative pelvic radiotherapy in relapsed ovarian cancers in terms of symptom control and PFS. METHODS: Twenty-three patients of ovarian cancers, heavily pretreated with chemotherapy and with recurrent or residual pelvic masses, were planned for palliative pelvic radiotherapy to the dose of 46-50 Gy in 23-25 fractions in 4.5-5 weeks. Symptom control and outcomes have been analyzed. RESULTS: Post-radiotherapy, abdominal pain was controlled in 15 out of 17 patients (88.2 %), bleeding per vaginum in all 5 patients and vaginal discharge stopped in 4 out of 5 patients (80 %). On follow-up, of 23 patients, 17 (74 %) had progressive disease post-radiation, and median time to disease progression was 10 months (range 1-49). On univariate analysis, increased PFS was observed in patients who received radiation late in their course of disease, those with serous histology, and with lesser disease bulk in pelvis (≤2 cm) prior to radiation initiation. CONCLUSION: Fractionated palliative pelvic radiotherapy is an efficient method for symptom palliation in relapsed ovarian cancers. Patients who are heavily pretreated with chemotherapy and have a small-volume pelvic disease may show a prolonged PFS with addition of pelvic radiotherapy. Indications of radiotherapy, however, need to be defined.
Authors: Robert Dinniwell; Michael Lock; Melania Pintilie; Anthony Fyles; Stephane Laframboise; Denny Depetrillo; Wilfred Levin; Lee Manchul; Joan Murphy; Amit Oza; Barry Rosen; Jeremy Sturgeon; Michael Milosevic Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-01 Impact factor: 7.038
Authors: A W Fyles; A J Dembo; R S Bush; W Levin; L A Manchul; J F Pringle; G A Rawlings; J F Sturgeon; G M Thomas; J Simm Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: F A Raja; N Counsell; N Colombo; J Pfisterer; A du Bois; M K Parmar; I B Vergote; A Gonzalez-Martin; D S Alberts; M Plante; V Torri; J A Ledermann Journal: Ann Oncol Date: 2013-11-04 Impact factor: 32.976
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: A J Dembo; R S Bush; F A Beale; H A Bean; J F Pringle; J Sturgeon; J G Reid Journal: Am J Obstet Gynecol Date: 1979-08-01 Impact factor: 8.661
Authors: Anish A Butala; Roshal R Patel; Shwetha Manjunath; Nawar A Latif; Ashley F Haggerty; Joshua A Jones; Neil K Taunk Journal: Adv Radiat Oncol Date: 2020-11-25